THE INFLUENCE OF ATORVASTATIN ON OMENTIN-1 LEVEL AND INSULIN RESISTANCE IN PATIENTS WITH CORONARY ARTERY DISEASE AND OBESITY

Authors

  • T. А. Maksymets Danylo Halytskyі Lviv National Medical University

DOI:

https://doi.org/10.11603/2415-8798.2018.3.9413

Keywords:

obesity, adipokines, omentin-1, insulin resistance, HOMA index, ischemic heart disease

Abstract

Adipose tissue is a powerful endocrine organ, which synthesizes significant amount of biologically active substances – adipokines. Due to adipokine dysfunction, a spectrum of diseases associated with obesity appears, namely, coronary artery disease, diabetes mellitus, hypertension and oncology. Hyperinsulinemia and insulin resistance play a significant role in pathogenesis of cardiometabolic complications in patients with obesity. They trigger a pathological cascade of reactions leading to cardiovascular diseases. Omentin-1 possesses anti-atherogenic action and it can modify peripheral effects of insulin.

The aim of the study – to analyze changes in omentin-1 concentration and the condition of insulin resistance in patients with coronary artery disease and obesity during atorvastatin treatment.

Materials and Methods. 55 patients with obesity were examined. They had general clinical examination; blood lipids, uric acid level and liver enzymes; glycated hemoglobin, glucose, insulin with the calculation of HOMA index and omentin-1 concentration was determined. Patients were divided into two groups: the group 1 – 20 patients with obesity, who did not suffer from CAD and did not take atorvastatin, and the group 2 – patients with CAD and obesity, who took atorvastatin. Determination of these indices was performed for patients of the group 2 in dynamics in 12 months.

Results and Discussion. In the group of patients with CAD and obesity, who took atorvastatin, lipid levels were reliably lower, but levels of fasting glucose concentration, uric acid and liver enzymes were higher than in the patients who did not take the drug. Elevation of omentin-1 in blood serum was observed in 12 months in patients with CAD and obesity simultaneously with the increase in insulin level and the decrease in tissue sensitivity to it.

Conclusions. Intake of atorvastatin by patients with coronary artery disease and obesity is accompanied by elevation of insulin concentration, intensification of insulin resistance and increase in omentin-1 level.

Downloads

Published

2018-10-16

How to Cite

Maksymets T. А. (2018). THE INFLUENCE OF ATORVASTATIN ON OMENTIN-1 LEVEL AND INSULIN RESISTANCE IN PATIENTS WITH CORONARY ARTERY DISEASE AND OBESITY. Bulletin of Scientific Research, (3), 39–42. https://doi.org/10.11603/2415-8798.2018.3.9413

Issue

No. 3 (2018)

Section

INTERNAL MEDICINE

License

Authors who sent their manuscript to "Вісник наукових досліджень. Bulletin of Scientific Research" Surgery agree to the following terms:

a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal. Результат пошуку зображень за запитом "CC-BY logo"         

b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.

c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)